A Study of Quality Assurance and Prescribing Practices in Generic Medicine Use in India

Generic medicines support affordable healthcare in India, but their appropriate use depends on pharmaceutical quality, regulatory oversight, and informed prescribing and dispensing practices. This study examines how quality-assurance systems and healthcare professionals’ decisions influence the acceptance and use of generic medicines, with particular attention to pharmaceutical equivalence, bioequivalence, laboratory standards, and substitution practices. It employs a descriptive and analytical design based exclusively on published scientific studies, official pharmaceutical guidelines, regulatory publications, and government reports. Purposively selected documentary evidence is examined through qualitative interpretation and descriptive comparisons; no primary survey, laboratory experiment, or original inferential analysis is undertaken. The findings show that lower prices do not necessarily indicate inferior pharmaceutical quality. In a comparative investigation in Kerala, all 131 sampled branded and generic medicines satisfy the assessed pharmacopoeial parameters, while generic products cost an average of 48.6% less. However, results from selected samples cannot establish nationwide quality compliance. Evidence on prescribing reveals differences in professional confidence: approximately 84% of government physicians and 64% of private physicians in one study consider generics equally safe and effective, while substantial proportions request further information on bioequivalence. Pharmacy-level evidence highlights the importance of patient counselling, medicine availability, and coordination with prescribers. The introduction of 121 new monographs in Indian Pharmacopoeia 2026 and government-supported batch testing illustrate continuing quality-assurance efforts. The study concludes that wider, appropriate generic medicine use requires transparent product-quality evidence, stronger professional education, consistent regulatory monitoring, and legally compliant substitution practices. These measures promote clinical confidence, patient safety, and access to affordable treatment.